Decitabine for Injection.

Function and indication:
Applicable to patients with first-time or retreatment myelodysplastic syndrome (MDS) with intermediate-2 and high-risk in the IPSS scoring system, including primary and secondary MDS, and all subtypes according to FAB classification: refractory anemia, refractory anemia with increased ring sideroblasts, refractory anemia with excessive primitive cells, refractory anemia with increased primitive cells-transition type, chronic myelomonocytic leukemia.
Adverse reactions:
Neutropenia, thrombocytopenia, anemia, weakness, fever, nausea, cough, petechiae, constipation, diarrhea, hyperglycemia.
Contraindications:
This product is contraindicated in patients with known allergy to decitabine.Decitabine for injection is used for patients with myelodysplastic syndrome (MDS), including primary and secondary MDS.